Xeris Biopharma posts Q1 2026 profit with EPS $0.01 on $83.1M revenue, beats estimates and raises 2026 guidance to $380–$390M
- Q1 2026 results represent a return to net income for Xeris Biopharma.
Thursday, May 7, 2026
Xeris books profit, ups guidance
Ligand Q1 2026 revenue $51.7M and adjusted EPS $1.63, reaffirms raised 2026 guidance
Ligand Pharmaceuticals posts Q1 2026 revenue $51.7M and adjusted EPS $1.63, reaffirms raised 2026 guidance
- Q1 2026 results driven by 56% royalty growth, contributing to revenue of $51.7 million
- Company reaffirms previously raised 2026 guidance, including partial-year contribution from pending XOMA Royalty acquisition
Akebia Q1 loss $0.03 per share on $53.5M revenue misses estimates for $0.01 loss on $56.5M revenue
Akebia Therapeutics Q1 loss $0.03 per share on $53.5M revenue misses estimates for $0.01 loss on $56.5M revenue
- Akebia reported Q1 2026 net loss totaling $9.1 million, compared with revenue of $53.5 million.
- Vafseo net product revenue rose to $15.8 million in Q1 2026.
- Company said $162.6 million cash should fund operations for at least two years while advancing kidney disease trials.
Evolent Q1 loss, beats on adjusted EPS, misses revenue, 2 new revenue agreements
Evolent Health posts Q1 loss, beats on adjusted EPS, misses revenue, unveils two new revenue agreements
- Evolent Health reported Q1 2026 loss of $0.24 per share on a GAAP basis.
- Adjusted Q1 2026 loss was $0.02 per share, beating analyst expectations for the quarter.
- Q1 2026 revenue totaled $496.2 million, below the $531.8 million analyst forecast.
- New Performance Suite expansion agreement is expected to generate over $200 million in annual revenue.
- Company reiterated full-year 2026 revenue and adjusted EBITDA guidance alongside its first quarter 2026 results.
Amylyx completes Phase 3 LUCIDITY enrollment, starts U.S. expanded access program for avexitide
Amylyx completes Phase 3 LUCIDITY enrollment, starts U.S. expanded access program for avexitide in post-bariatric hypoglycemia
- Amylyx Pharmaceuticals reported Q1 2026 net loss of $41.3 million.
- Ended Q1 2026 with $279.8 million in cash and an expected runway into 2028.
Ironwood Q1 profit of $40.8 m on $106.5 m revenue, guides 2026 revenue to $450-$475 m
Ironwood Pharmaceuticals posts Q1 profit of $40.8 million on $106.5 million revenue, guides 2026 revenue to $450-$475 million
- Q1 2026 net income reported as $41 million, with LINZESS U.S. sales up 97% YoY
- Ironwood Pharmaceuticals affirms its 2026 guidance after releasing Q1 2026 financial results
Lantheus wins FDA approval for PYLARIFY TruVu and beats Q1 2026 estimates
Lantheus wins FDA approval for PYLARIFY TruVu and beats Q1 2026 estimates with revenue $377.3M, adjusted EPS $1.46
- FDA approval of PYLARIFY TruVu was disclosed in a recent Lantheus SEC filing.
- Q1 2026 revenue of $377.3 million exceeded the Zacks consensus estimate of $358.1 million.
- Q1 2026 adjusted EPS of $1.46 beat the Zacks consensus estimate of $1.25.
- Company reaffirmed full-year 2026 revenue and earnings guidance following the Q1 2026 results.
Subscribe to:
Posts (Atom)